Although biomarkers have been developed, which correlate the response of lung cancer patients to anti-PD1/anti–PD-L1 therapy, defining the cellular and molecular pathways that regulate this response remains poorly understood. This evidence concerns the gene PDCD1 and lung carcinoma.